Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 16/20 | 0.82 |
| ▸ | THRA | P10827 | 12/20 | 0.82 |
| ▸ | RORC | P51449 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5382651 | 0.91 | THRB (0.78) | THRBTHRARORCKDM4E | |
| SCHEMBL5392866 | 0.90 | THRA (1.00) | THRBTHRA | |
| SCHEMBL5396335 | 0.90 | THRB (0.74) | THRBTHRARORCKDM4ECA12 | |
| SCHEMBL5385620 | 0.90 | THRB (0.67) | THRBTHRARORC | |
| SCHEMBL7204449 | 0.89 | THRB (0.75) | THRBTHRARORCKDM4ECA12 | |
| SCHEMBL5406458 | 0.88 | THRB (0.65) | THRBTHRARORCCA12CA1 | |
| SCHEMBL5406523 | 0.85 | THRB (0.72) | THRBTHRARORCCA12CA1 | |
| SCHEMBL5387224 | 0.85 | THRB (0.81) | THRBTHRARORC | |
| SCHEMBL5391643 | 0.85 | THRB (0.60) | THRBTHRARORC | |
| SCHEMBL5397843 | 0.84 | THRB (0.60) | THRBTHRARORCCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199265-B2 | Thyroid receptor ligands, pharmaceutical compositions comprising them and their use in the treatment of disorders influenced by thyroid hormones | KARO BIO AB (SE) | 2007-04-03 | — | — | US | disclosed |
| US-20040097589-A1 | Thyroid receptor ligands, pharmaceutical compositions comprising them and their use in the treatment of disorders influenced by thyroid hormones | KARO BIO AB (SE) | 2004-05-20 | — | — | US | disclosed |
| EP-1296936-A1 | THYROID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE IN THE TREATMENT OF DISORDERS INFLUENCED BY THYROID HORMONES | KARO BIO AB (SE) | 2003-04-02 | — | — | EP | disclosed |
| WO-2001098256-A1 | THYROID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND THEIR USE IN THE TREATMENT OF DISORDERS INFLUENCED BY THYROID HORMONES | KARO BIO AB (SE) | 2001-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097589-A1 | Thyroid receptor ligands, pharmaceutical compositions comprising them and their use in the treatment of disorders influenced by thyroid hormones | TSHR, THRA, THRB | THRB 3/4885THRA 2/4885RORC 220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.